Mary Kay Inc. Caps Off Landmark Scientific Credentialing Year at 73rd Society of Cosmetic Chemists Meeting
In 2019, Mary Kay Inc. continued its decades-long commitment to skin science research by revealing the results of multiple groundbreaking studies and fostering academic discussion with industry peers at scientific symposiums around the globe. Most recently, Mary Kay was in New York City for the 73rd Society of Cosmetic Chemists Meeting, where the brand sponsored, collaborated, and explored applications of skin microbiome with leading experts in the field.
“New research suggests that microbes play an important role in overall skin health, and as leading skincare innovators, Mary Kay is heavily invested in further exploration of their impact,” said Dr. Lucy Gildea, Chief Scientific Officer at Mary Kay. “We have a commitment to take an active role in the beauty and scientific communities through participation in global dermatological conferences like the Society of Cosmetic Chemists Meeting, where we can share and learn from other scientific experts to help us develop more effective products.”
The Society of Cosmetic Chemists Meeting convenes over 1,300 attendees from some of the top cosmetic and personal care brands and manufacturers. Participants are encouraged to engage with speakers presenting the latest research and innovations of interest to cosmetic scientists, exchange ideas with peers, and reconnect with colleagues from around the globe.
Mary Kay sponsored the educational session at the meeting, including topics Quorum Quenching: the New Way to Keep Microbiome Under Control, Exploring New Applications in Personal Care: Balancing our Skin Microbiota, Global Microbiome Effects, and Temporal Variation of the Facial Skin Microbiome.
Additional 2019 Scientific Research and Credentialing
The 73rd Society of Chemists Meeting is the latest event in a series of Mary Kay presentations with the scientific and academic communities that reinforce the brand’s longstanding commitment to advancing skin health research and development. Every year, Mary Kay conducts hundreds of thousands of scientific tests on products and ingredients to ensure the highest standards of safety, quality and performance. Mary Kay holds more than 1,500 patents for products, technologies and packaging designs in its global portfolio. Recently, the company announced the opening of a more than $100 million state-of-the-art manufacturing and R&D facility in Lewisville, Texas.
In 2019, Mary Kay focused on three pillars in its commitment to skin health, including pollution; skin barrier health and sensitive skin; and the understanding of skin aging and strategies to intervene:
Pollution and Skin Health
- May: Mary Kay sponsored an exclusive symposium on the impact of pollution on skin health in the Latin America region at the prestigious Reunión Anual de Dermatólogos Latinoamericanos (RADLA) in Buenos Aires, Argentina. Dr. Gildea moderated this symposium with 3 expert Brazilian dermatologists sharing research on the impact of air pollution on skin. It was concluded that antioxidants would be a viable way to counteract the negative effects of pollution on skin. Fortunately, Mary Kay also presented findings on an antioxidant complex that can help delay the premature signs of aging related to the damaging effects of air pollution.
-
June: Mary Kay the 24th World Congress of Dermatology in Milan, Italy. Mary Kay sponsored a Questions and Answers session with 2 dermatology experts on the impact of environmental stressors in Europe on skin. Dr. Michelle Hines, Global Upstream Research & Technology at Mary Kay hosted this event featuring two renowned Europe skin experts:
- Jean Krutmann, M.D., Professor & Director at Leibniz Research Institute for Environmental Medicine – Dusseldorf, Germany.
- Stefanie Williams, M.D., Dermatologist & Medical Director at EUDELO – London, United Kingdom.
- June: At the 5th Future of Formulations in Cosmetics Summit in Dusseldorf, Germany, Dr. Hines revealed Mary Kay’s ongoing research on an antioxidant complex that helps delay the onset of premature signs of aging related to the damaging effects of diesel exhaust particles (DEP) on skin cells. The breakthrough technology, found in the Mary Kay® TimeWise® Miracle Set 3D™ skin care line, provides a powerful free-radical fighting regimen with an exclusive, patent-pending, three-dimensional approach to skin aging.
Skin Barrier Health and Sensitive Skin
- March: At the 20th World Dermatology Congress in Singapore, David Gan, Senior Principal Scientist at Mary Kay Inc., presented some new insights in evaluating and understanding facial redness. Based on this work, Mary Kay scientists identified skincare technology that helps reduce the production of pro-inflammatory proteins and enzymes in the skin and developed a cosmetic formulation containing these ingredients to effectively address facial redness using unique clinical measures.
- August: Mary Kay China’s Sr. Manager for Medical Affairs, Dr. Jenny Jiang, shared some strategies from Mary Kay research to improve the skin barrier function and facial redness at the Annual Meeting of the Dermatology Committee organized by the Chinese Association of Integrative Medicine in Lanzhou, Gansu Province, China. These findings may provide important insights to understanding sensitive skin.
-
November: Mary Kay was a symposium sponsor at the 44th annual meeting of The Japanese Society of Investigative Dermatology (JSID) in Aomori, Japan. Dr. Gildea moderated an educational symposium exploring environmental protection strategies against skin aging in Asians, protein response to skin inflammation and skin barrier defects. The panel featured three renowned dermatologists:
- Dr. Akimichi Morita, MD Ph.D., Department of Geriatric and Environmental Dermatology at Nagoya City University Graduate School of Medical Sciences
- Dr. Sang Eun Lee, MD Ph.D., Department of Dermatology, Gangnam Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine in Seoul, Korea
- Dr. Gyohei Egawa, MD Ph.D., Department of Dermatology, Kyoto University Graduate School of Medicine
Understanding of Skin Aging and Skin Health and Strategies to Intervene
- March: At the Skin of Color Society Symposium in Washington. D.C., Dr. Shoná Burkes-Henderson, Associate Principal Scientist, Clinical Research, revealed new research on navy bean extract and its ability to regulate melanogenesis, leading to an improvement in uneven skin tone and facial hyperpigmentation. Dr. Burkes-Henderson also presented a new approach to help improve facial erythema, or redness, at the American Academy of Dermatology Annual Meeting.
- May: Mary Kay Associate Principal Scientist Dr. Tiffany Carle attended 77th Annual Meeting of the Society for Investigative Dermatology in Chicago, where she presented new data from analyzing the effects of a serum containing five botanical fruit extracts known to be rich in vitamin C on skin appearance. As part of this study, Mary Kay researchers treated artificial skin tissue with this serum and utilized a genomic approach to understand how the serum affected the skin.
- June: Mary Kay sponsored the University of the Philippines Medical Alumni Society of America (UPMASA) 34th Annual Grand Convention (AGC) in Dallas. The conference convened more than 500 doctors from the U.S. and the Philippines to discuss topics ranging from dermatology to orthopedics and neurology.
- September: Mary Kay shared its latest research targeting the causes and underlying mechanisms of slackened skin at the 49th Annual Meeting of the European Society for Dermatological Research (ESDR) held in Bordeaux, France. Dr. Michelle Hines shared data on technology that targeted slackened skin leading to improvement in skin clinical measures.
- September: Mary Kay presented findings on research experiments that demonstrated how sunscreen viscosity, a property that effects application to skin, can be adjusted using processing parameters at the 2019 Sunscreen Symposium presented by the Florida chapter of the Society of Cosmetic Chemists in Lake Buena Vista, Florida.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 56 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191220005081/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 03:00:00 EET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 01:34:00 EET | Press release
Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of the EIOS:VSE stock reflects this strength: Price per Share (PPS): +132% in the first half (H1) of 2025, stabilizing at a +116% YTD increase. Daily Trading Volume: peaks of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 22:37:00 EET | Press release
500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to strengthen Morocco’s innovation and digital competitiveness by accelerating high-potential founders and providing the training and financing pa
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 18:00:00 EET | Press release
Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218764112/en/ Image courtesy of Neural Concept (L-R clockwise from top) Jonathan Donier, CSO & Co-founder; Thomas von Tschammer, Managing Director US & Co-founder; Théophile Allard, CTO & Co-founder; Pierre Baqué CEO & Co-founder; Philippe Cuendet, COO Neural Concept is redefining engineering workflows with CAD-native enterprise AI that understands geometry, constraints and design intent. By helping its customers build and deploy physics-aware design copilots, the platform enables teams to explore millions of design options earlier and avoid costly la
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 17:57:00 EET | Press release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special? MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
